semaglutide in kidney disease FLOW clinical Trial (funded by Novo Nordisk): showed 24% reduction the risk of disease-related events in people with type 2 diabetes and chronic kidney compared to placebo. Investigators Effects of Semaglutide on Chronic
Description
A person shouldnt stay on the liquid diet for more than a few days unless under the care of a healthcare provider because they wouldnt be getting enough calories or proper nutrition
Some patients may experience nausea, digestive discomfort, or appetite changes
Eating smaller meals can help reduce this side effect
In line with UK Summary of Product Characteristics (SmPC) guidance for approved agents in this class: Retatrutide should not be used during pregnancy
Compounded semaglutide is dosed in micrograms (mcg), often in concentrations of 2.5 mg/mL or 5 mg/mL depending on your prescription
Headache: Occasional, typically transient
